ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 105,23
0,13%
Dow Jones
39 069,59
0,01%
DAX
18 709,41
0,08%
Brent Oil
82,335
0,43%
Bitcoin
68 428,52
-0,12%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. eFFECTOR Therapeutics Inc (EFTR)

  7. eFFECTOR Therapeutics Inc (EFTR) Actualités

EFTR

eFFECTOR Therapeutics (EFTR)

eFFECTOR Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:EFTR
DateHeureSourceTitreSymboleSociété
21/02/202423h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EFTReFFECTOR Therapeutics Inc
10/02/202402h14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EFTReFFECTOR Therapeutics Inc
30/01/202414h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EFTReFFECTOR Therapeutics Inc
26/01/202422h32Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EFTReFFECTOR Therapeutics Inc
10/01/202414h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:EFTReFFECTOR Therapeutics Inc
13/11/202322h25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EFTReFFECTOR Therapeutics Inc
27/06/202312h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:EFTReFFECTOR Therapeutics Inc
23/06/202322h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:EFTReFFECTOR Therapeutics Inc
08/06/202312h15Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:EFTReFFECTOR Therapeutics Inc
08/06/202312h07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:EFTReFFECTOR Therapeutics Inc
16/05/202314h04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:EFTReFFECTOR Therapeutics Inc
12/05/202322h24Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:EFTReFFECTOR Therapeutics Inc
12/05/202322h19Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:EFTReFFECTOR Therapeutics Inc
12/05/202322h13Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:EFTReFFECTOR Therapeutics Inc
09/05/202322h23Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:EFTReFFECTOR Therapeutics Inc
08/03/202322h17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:EFTReFFECTOR Therapeutics Inc
07/03/202323h26Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:EFTReFFECTOR Therapeutics Inc
14/02/202312h35Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:EFTReFFECTOR Therapeutics Inc
17/11/202206h41TipRanksAnalysts’ Top Healthcare Picks: CureVac (CVAC), eFFECTOR Therapeutics (EFTR)NASDAQ:EFTReFFECTOR Therapeutics Inc
07/11/202223h35TipRanksMizuho Securities Reaffirms Their Buy Rating on eFFECTOR Therapeutics (EFTR)NASDAQ:EFTReFFECTOR Therapeutics Inc
28/09/202222h43Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:EFTReFFECTOR Therapeutics Inc
14/09/202217h45TipRanksMizuho Securities Keeps Their Buy Rating on eFFECTOR Therapeutics (EFTR)NASDAQ:EFTReFFECTOR Therapeutics Inc
11/08/202222h56Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:EFTReFFECTOR Therapeutics Inc
11/08/202206h15TipRanksJMP Securities Sticks to Their Buy Rating for eFFECTOR Therapeutics (EFTR)NASDAQ:EFTReFFECTOR Therapeutics Inc
10/08/202202h25TipRanksMizuho Securities Sticks to Its Buy Rating for eFFECTOR Therapeutics (EFTR)NASDAQ:EFTReFFECTOR Therapeutics Inc
09/08/202222h01GlobeNewswire Inc.eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:EFTReFFECTOR Therapeutics Inc
08/08/202211h30GlobeNewswire Inc.eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical OfficerNASDAQ:EFTReFFECTOR Therapeutics Inc
07/06/202214h00GlobeNewswire Inc.eFFECTOR Therapeutics to Present at JMP Securities Life Sciences ConferenceNASDAQ:EFTReFFECTOR Therapeutics Inc
06/06/202206h45TipRanksJMP Securities Thinks eFFECTOR Therapeutics’ Stock is Going to RecoverNASDAQ:EFTReFFECTOR Therapeutics Inc
05/06/202223h00GlobeNewswire Inc.eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical ActivityNASDAQ:EFTReFFECTOR Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:EFTR

Dernières Valeurs Consultées

LSE
0QY4
Las Vegas Sands
ASX
YM1JOP
BOV
RAILH210
RAILH210 Ex:20,91
USOTC
DSITF
Currys (PK)
CEGG
BTMUSDT
Bytom
IDCM
QRGETH
Quick Response Gibraltar
COIN
OSCUSD
COIN
SKELUSD
COIN
NIHAOUSD
NiHao
EU
INHEU
Hsbc HEU Inav
BIT
INRG
Exchange Traded
BIT
F12644
Vontobel Financial Produ...
TG
MIVB
Amundi Index Solutions
UPBT
MOBIBTC
Mobius
BIT
F14024
Vontobel Financial Produ...
NASDAQ
XLKS
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés